MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Rheumatology

Section

Rheumatology

149 articles

Ask AI
All specialtiesRheumatologynewsClinical UpdatesCardiologyOncology

Latest updates

news

Targeting Modifiable Risks to Prevent Knee Osteoarthritis

A large systematic review identified prior knee injury, older age, and high bone mineral density as predictors of incident radiographic knee osteoarthritis; overweight/obesity and prior injury explained ~14% of cases—highlighting prevention

Nov 1, 2025
news

Physical Activity and Risk of Knee Replacement in Radiographic Osteoarthritis

In a 9-year OAI cohort analysis, baseline self-reported moderate physical activity was linked to lower knee replacement risk in KL grade 2 but to higher risk in KL >2; high activity showed no clear effect. Results support severity-tailor

Nov 1, 2025
news

Baseline Sarcopenia Predicts Faster Knee Osteoarthritis Progression and Much Higher Risk of Knee Replacement

In a longitudinal analysis of 4,316 Osteoarthritis Initiative participants, baseline sarcopenia screened by SARC-F and chair-stand testing was associated with accelerated radiographic and symptomatic knee OA progression over 24–48 months an

Nov 1, 2025
news

Chondrocalcinosis Predicts Incident Knee Osteoarthritis

Two large longitudinal cohorts show baseline chondrocalcinosis is associated with ~75% higher odds of developing radiographic knee osteoarthritis over long-term follow-up, suggesting calcium crystal deposition may be a contributing factor i

Nov 1, 2025
Diabetes & Endocrinology

SGLT-2 Inhibitors and Autoimmune Rheumatic Disease Risk Reduction in Type 2 Diabetes: Insights from a Korean Nationwide Cohort

A large South Korean cohort study suggests that sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the incidence of autoimmune rheumatic diseases by 11% compared to sulfonylureas in adults with type 2 diabetes, indicating potential i

Oct 31, 2025Sign in to read
Nephrology

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors’ bone safety in this population.

Oct 30, 2025Sign in to read
news

Dual αvβ6 and αvβ1 Integrin Inhibition Reduces Lung Collagen Deposition in Idiopathic Pulmonary Fibrosis: Insights from a Phase 2 Clinical Trial

This phase 2 trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, significantly reduces active type I collagen deposition in IPF lungs, indicating antifibrotic potential and favorable lung remodeling over 12 weeks.

Oct 28, 2025Sign in to read
Internal Medicine

Emerging Promise of Telitacicept in Treating Systemic Lupus Erythematosus: Insights from a Phase 3 Trial

This article reviews a pivotal phase 3 trial demonstrating telitacicept’s efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.

Oct 25, 2025
Nephrology

FDA Approves Roche’s Obinutuzumab for Lupus Nephritis: Promising Advances in B-cell Targeted Therapy

The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis managem

Oct 24, 2025
Nephrology

Avacopan in Older Adults with ANCA-Associated Vasculitis: Efficacy and Safety Confirmed in ADVOCATE Post Hoc Analysis

This post hoc analysis of the ADVOCATE trial demonstrates that avacopan is effective and safe for treating ANCA-associated vasculitis in patients aged 65 and older, achieving sustained remission with reduced glucocorticoid exposure and toxi

Oct 23, 2025
Nephrology

Avacopan Combined with Cyclophosphamide in ANCA-Associated Vasculitis: A Safer and Effective Alternative to Prednisone Taper

Avacopan, a complement C5a receptor inhibitor, shows comparable remission rates to prednisone taper in ANCA-associated vasculitis patients receiving cyclophosphamide, with benefits of lower relapse, improved kidney function, and reduced glu

Oct 23, 2025Sign in to read
Nephrology

Real-World Effectiveness of Rituximab and Cyclophosphamide in Severe ANCA-Associated Vasculitis: Insights from J-CANVAS

A comprehensive review of a Japanese cohort study assessing rituximab and cyclophosphamide efficacy in severe microscopic polyangiitis and GPA, highlighting clinical implications.

Oct 23, 2025
news

Unveiling Early Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors and Validation of Screening Approaches in the SAIL-RA Cohort

This article examines the prevalence, risk factors, and diagnostic screening strategies for rheumatoid arthritis-associated interstitial lung disease (RA-ILD) in early rheumatoid arthritis, highlighting age and disease activity as key predi

Oct 19, 2025
Hematology-Oncology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use a

Oct 14, 2025Sign in to read
Hematology-Oncology

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.

Oct 14, 2025
Hematology-Oncology

VEXAS Anemia: Unraveling the Mosaic Erythroblastopenia in a Novel Autoinflammatory Syndrome

This study reveals that VEXAS syndrome-associated anemia results from a mosaic erythroblastopenia due to selective UBA1 mutations in early erythroid precursors, advancing understanding of its pathophysiology and therapeutic implications.

Oct 14, 2025
news

Evaluating Pilates for Knee Osteoarthritis: Efficacy, Safety, and Clinical Insights from Recent Meta-Analysis

A systematic review and meta-analysis of RCTs indicates Pilates may improve pain and function in knee osteoarthritis patients, though evidence quality is low and safety data insufficient. Caution is warranted in interpreting results, highli

Oct 11, 2025
Neurology

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.

Oct 10, 2025
news

Diagnosing and Managing Methotrexate-Induced Osteopathy in Rheumatologic Practice

Methotrexate-induced osteopathy, predominantly affecting postmenopausal women with rheumatoid or psoriatic arthritis, presents as stress fractures in the lower limbs. Early MRI or bone scintigraphy aids diagnosis, and discontinuing methotre

Oct 9, 2025
news

Guardians Within: Unveiling the Nobel-Winning Discovery of Regulatory T Cells and Their Crucial Role in Immune Balance

The 2025 Nobel Prize honors the groundbreaking discovery of regulatory T cells (Tregs), key immune modulators that maintain tolerance and prevent autoimmunity, inspiring new therapies for autoimmune disease, transplantation, and cancer.

Oct 6, 2025
Previous
6 / 8
1…45678
Next

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.